医学
观察研究
1型糖尿病
肥胖
糖尿病
减肥
重症监护医学
2型糖尿病
外科
梅德林
风险因素
2型糖尿病
前瞻性队列研究
风险评估
儿科
胰岛素
内科学
系统回顾
并发症
代谢综合征
疾病
作者
Sebastian Mitchell,Ketaki Patwardhan,James Lucocq,Georgios Geropoulos,PJ Lamb,Omar Ghanem,Roland H. Stimson,Andrew Robertson
摘要
MBS achieves weight loss and reduces insulin requirements in adults with type 1 diabetes mellitus and obesity, but glycaemic improvements are minimal. Given the observational evidence base and inconsistent safety reporting, true metabolic risk remains uncertain. High-quality prospective studies with standardised outcome definitions are needed.
科研通智能强力驱动
Strongly Powered by AbleSci AI